Skip to content
Search

Latest Stories

New NHS patient choice scheme offers 5 options, but nursing shortages persist

New NHS patient choice scheme offers 5 options, but nursing shortages persist
Royal College of Nursing CE urges caution amidst new NHS patient choice pilot scheme rollout

"Patients deserve choice, but wherever they go they will find vacant nursing posts and overstretched services," responded Professor Pat Cullen, RCN General Secretary and Chief Executive, to the introduction of the new pilot scheme for out-of-hospital patient care.

The NHSE and the DHSC have announced a new pilot scheme commencing in autumn "offering patients a choice of where they receive out-of-hospital care".


Under the initiative, individuals requiring treatment outside of hospitals will have the opportunity to select from a range of providers across both the NHS and the independent sector.

Patients can select their care provider for in-hospital consultant-led services post-GP consultation, offering a choice from at least 5 providers with details on waiting times, distance, and quality.

The new pilots schemes are set to expand patient choice thereby enhancing outcomes and convenience to reduce waiting lists and improve the quality of healthcare services.

Considered as "the largest expansion of choice within the NHS in a decade" by the prime minister, the scheme under the expanded choice initiative offer endoscopy, nutrition, and podiatry, and mental health.

The Prime Minister highlighted that expanding patient choice will expedite access to necessary care and is integral to their strategy for reducing waiting lists.

He cited a significant reduction of nearly 200,000 since September as evidence of progress.

The NHSE also plans to collaborate with integrated care boards (ICBs) to launch these pilots locally, with participation expected from ICBs across the nation.

While the announcement has garnered some positive reactions from various stakeholders, including Chief Executive of the Patients Association, Rachel Power;

RCN General Secretary and Chief Executive, Professor Pat Cullen voiced concern over nurse staff.

She responded to the announcement stating, "today's announcement does nothing to change the 34,000 nurse vacancies in England's NHS.

"While patients are supposedly being given choice, nursing staff are choosing to leave the profession for jobs overseas where they are valued and paid fairly."

Emphasising workforce shortages, she stressed that patients will encounter “vacant nursing posts and overstretched services,” with nursing staff facing “relentless pressure and chronic shortages across every setting.”

Professor Cullen further asserted that reducing waiting lists necessitates direct investment in the nursing workforce, highlighting the need for substantial action rather than superficial measures.

Pilot services encompass hearing aid care, diagnostic tests like endoscopy, dietetics, ambulatory ECG, and podiatry.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less